← 產業報告目錄

RNA-based Therapeutics Market Size, Share & Trends Analysis Report By Product (Vaccines, Drugs), By Type (mRNA Therapeutics, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotide (ASO) Therapeutics, RNA Aptamer, Other Therapeutics), By Indication (Infectious Diseases, Rare Genetic Diseases/Hereditary Diseases, Oncology, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), Others), By End User (Hospitals and Clinics, Research Settings), By Region, And By Segment Forecasts, 2025-2034

出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-15頁數 185報告編號 INSIGHTACE-f17edc7bee

授權報價

Single User PDF$4,500 USD
Global Site License PDF$9,500 USD
洽詢購買 申請 Sample

報告摘要

The RNA-based Therapeutics Market on a global scale was estimated at USD 12.4 Billion in 2024 and is projected to attain USD 22.6 Billion by 2034, with a projected CAGR of 6.5% between 2025 and 2034. The RNA-based Therapeutics sector involves key industry insights & findings from the report: The growing biopharmaceutical sector, characterized by increased investment and interest in innovative therapies, is propelling the rna-based therape. This domain has witnessed considerable transformation owing to technological breakthroughs and shifting healthcare dynamics. The market's upward path is underpinned by escalating healthcare spending, technological evolution, and the escalating focus on personalized and precision-based approaches in healthcare. The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion. Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region projected to deliver the strongest growth trajectory through the forecast period, underpinned by demographic shifts and policy support. Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players. This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global RNA- based Therapeutics Market Snapshot Chapter 4. Global RNA- based Therapeutics Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Investment and Funding Analysis 4.6. Industry Analysis – Porter's Five Forces Analysis 4.7. Competitive Landscape & Market Share Analysis 4.8. Impact of Covid-19 Analysis Chapter 5. Market Segmentation 1: by Product Estimates & Trend Analysis 5.1. by Product & Market Share, 2024 & 2034 5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Product: 5.2.1. Vaccines 5.2.2. Drugs Chapter 6. Market Segmentation 2: by Type Estimates & Trend Analysis 6.1. by Type & Market Share, 2024 & 2034 6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type: 6.2.1. mRNA Therapeutics 6.2.2. RNA Interference (RNAi) Therapeutics 6.2.3. Antisense Oligonucleotide (ASO) Therapeutics 6.2.4. RNA Aptamer 6.2.5. Other Therapeutics Chapter 7. Market Segmentation 3: by Indication Estimates & Trend Analysis 7.1. by Indication & Market Share, 2024 & 2034 7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Indication: 7.2.1. Infectious Diseases 7.2.2. Rare Genetic Diseases/Hereditary Diseases 7.2.3. Oncology 7.2.4. Ophthalmology 7.2.5. Hematological Disorders 7.2.6. Acute Hepatic Porphyria (AHP) 7.2.7. Others Chapter 8. Market Segmentation 4: by End User Estimates & Trend Analysis 8.1. by End User & Market Share, 2024 & 2034 8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End User: 8.2.1. Hospitals and Clinics 8.2.2. Research Settings Chapter 9. RNA- based Therapeutics Market Segmentation 5: Regional Estimates & Trend Analysis 9.1. North America 9.1.1. North America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034 9.1.2. North America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034 9.1.3. North America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034 9.1.4. North America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034 9.1.5. North America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034 9.2. Europe 9.2.1. Europe RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034 9.2.2. Europe RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034 9.2.3. Europe RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034 9.2.4. Europe RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034 9.2.5. Europe RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034 9.3. Asia Pacific 9.3.1. Asia Pacific RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034 9.3.2. Asia Pacific RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034 9.3.3. Asia-Pacific RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034 9.3.4. Asia-Pacific RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034 9.3.5. Asia Pacific RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034 9.4. Latin America 9.4.1. Latin America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034 9.4.2. Latin America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034 9.4.3. Latin America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034 9.4.4. Latin America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034 9.4.5. Latin America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034 9.5. Middle East & Africa 9.5.1. Middle East & Africa RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034 9.5.2. Middle East & Africa RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034 9.5.3. Middle East & Africa RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034 9.5.4. Middle East & Africa RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034 9.5.5. Middle East & Africa RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034 Chapter 10. Competitive Landscape 10.1. Major Mergers and Acquisitions/Strategic Alliances 10.2. Company Profiles 10.2.1. Akcea Therapeutics Inc, 10.2.2. Biogen Inc., 10.2.3. Noxxon Pharma, 10.2.4. Ophthotech Corporation, 10.2.5. Olix Pharmaceuticals, 10.2.6. GlaxoSmithKline Plc, 10.2.7. Sanofi S.A, 10.2.8. Alnylam Pharmaceuticals, 10.2.9. Ionis Pharmaceuticals, 10.2.10. Benitec Biopharma Ltd, 10.2.11. Acuitas Therapeutics, 10.2.12. Arbutus Biopharma, 10.2.13. Silence Therapeutics Plc, 10.2.14. Enzon Pharmaceuticals Inc, 10.2.15. Bio-Path Holdings Inc., 10.2.16. Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc.), 10.2.17. Antisense Therapeutics Ltd., 10.2.18. Gene Signal, 10.2.19. Gradalis, 10.2.20. iCo Therapeutics, 10.2.21. Lorus Therapeutics (Aptose Biosciences), 10.2.22. miRagen Therapeutics,

量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理,提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們